Australia markets open in 8 hours 56 minutes

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
77.64+0.36 (+0.47%)
As of 10:04AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close77.28
Open77.53
Bid77.38 x 800
Ask77.56 x 900
Day's range77.01 - 78.25
52-week range65.30 - 181.83
Volume87,570
Avg. volume951,026
Market cap6.678B
Beta (5Y monthly)1.42
PE ratio (TTM)N/A
EPS (TTM)-8.02
Earnings date03 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est121.65
  • GlobeNewswire

    Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021

    CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, November 3, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2021 financial results and to provide a corporate update. The conference call may be accessed by dialing (844) 534-7313 for d

  • Motley Fool

    Is This Beaten Down Biotech a Bad News Buy?

    It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?

  • Motley Fool

    Why Sarepta Therapeutics Fell 14.7% This Week

    Sarepta Therapeutics (NASDAQ: SRPT), a biotech company that specializes in genetic therapies for rare diseases, dropped 14.7% this week, according to data from S&P Global Market Intelligence. To start the week, the company announced results from its three phase 3 trials for SRP-9001 to treat Duchenne muscular dystrophy (DMD), which is caused by gene mutations that disrupt the dystrophin protein that is crucial for muscle functions. The trials, which measured the response of SRP-9001 on 120 juvenile patients, said that patients improved on the North Star Ambulatory Assessment (NSAA) scale compared with untreated patients.